Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 8.6% on Friday . The company traded as high as GBX 4 ($0.05) and last traded at GBX 3.80 ($0.05). 48,430,910 shares traded hands during trading, an increase of 111% from the average session volume of 22,957,311 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Price Performance
The stock’s 50-day simple moving average is GBX 1.40 and its two-hundred day simple moving average is GBX 1.65. The firm has a market cap of £16.66 million, a P/E ratio of -400.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Read More
- Five stocks we like better than ImmuPharma
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- EV Sales Are Hitting Record Highs: 3 ETFs That Can Benefit
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Reasons Palo Alto May Be the Best Cybersecurity Stock in 2025
- What is a Dividend King?
- ServiceNow Targets New Highs With AI and Automation
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
